Cidara Therapeutics Inc.
Cidara Therapeutics Merger with Merck Sharp & Dohme LLC Complete
Summary
Cidara Therapeutics, Inc. has completed its merger with Merck Sharp & Dohme LLC, becoming a wholly owned subsidiary. The merger was finalized on January 7, 2026, following a tender offer that resulted in 88.3% of Cidara's shares being validly tendered. As part of the merger agreement, Cidara's equity incentive plans were terminated, and its board of directors and officers were replaced. Cidara's common shares will be delisted from Nasdaq and the company will terminate its registration under the Securities Exchange Act of 1934. The merger was governed by Section 251(h) of the Delaware General Corporation Law.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement